全乳放疗同步帕博利珠单抗诱发大疱性类天疱疮:病例报告与文献综述
本文报告一例50岁IIIA期三阴性乳腺癌患者,在新辅助化疗免疫治疗后行乳房切除术后辅助帕博利珠单抗,并于术后放疗(含区域淋巴结照射)期间发生大疱性类天疱疮。皮损初始位于照射野外,后累及照射区与非照射区皮肤及黏膜皮肤表面;活检及直接免疫荧光确诊。提示放疗与PD-1抑制可能存在协同免疫毒性,需警惕非典型放射性皮炎。
要点
- 放疗联合PD-1抑制剂可能协同诱发大疱性类天疱疮等免疫相关不良反应。
- 皮损初始在照射野外、后累及照射区,提示非典型放射性皮炎需警惕免疫毒性。
- 确诊需活检及直接免疫荧光,治疗常需全身激素和保激素药物,部分需永久停免疫治疗。
核心结论
- 放疗与帕博利珠单抗联合治疗期间发生的大疱性类天疱疮,其早期出现于放疗中且分布超出照射野,支持放疗与PD-1抑制存在协同交互作用。
研究设计与样本
- 个案报告:一例50岁IIIA期三阴性乳腺癌患者,接受新辅助化疗免疫治疗、乳房切除术后辅助帕博利珠单抗及术后放疗(含区域淋巴结照射)。
- 文献综述:文中汇总了PD-1抑制剂相关大疱性类天疱疮在同步放疗背景下的有限数据。
主要发现
- 患者在第7次放疗后出现大疱性皮损,初始位于照射野外,后进展累及照射区与非照射区皮肤及黏膜皮肤表面。
- 活检示表皮下疱性皮肤病,符合大疱性类天疱疮,重复活检直接免疫荧光确诊。
- 停用放疗和帕博利珠单抗,予全身糖皮质激素及保激素药物治疗,病程迁延复发,最终需永久停用免疫治疗。
临床怎么用
- 对放疗联合PD-1抑制剂患者,应高度怀疑免疫相关毒性,尤其当皮肤表现不典型于放射性皮炎时。
- 及时行皮肤活检及直接免疫荧光以明确诊断,并开展多学科管理。
局限性
- 本文为单例病例报告及文献综述,证据级别有限,不能确立因果关系或发生率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bullous pemphigoid (BP) is a rare autoimmune blistering disorder increasingly recognized as an immune-related adverse event associated with programmed cell death protein 1 inhibitors, with limited data describing its occurrence in the setting of concurrent radiation therapy (RT). We report a case of a 50-year-old woman with stage IIIB triple-negative breast cancer treated with neoadjuvant chemoimmunotherapy followed by mastectomy and adjuvant pembrolizumab who developed BP during postmastectomy RT with regional nodal irradiation. After 7 fractions, she developed bullous lesions initially outside the radiation field, with subsequent progression to involve both irradiated and nonirradiated skin as well as mucocutaneous surfaces. Biopsy demonstrated subepidermal vesicular dermatosis consistent with BP, later confirmed on repeat biopsy with direct immunofluorescence. RT and pembrolizumab were held, and she was treated with systemic corticosteroids and steroid-sparing therapy, although her course was prolonged and relapsing, ultimately requiring permanent discontinuation of immunotherapy. This presentation, including early onset during RT and distribution beyond the treatment field, supports a synergistic interaction between RT and programmed cell death protein 1 inhibition, potentially mediated by enhanced antigen presentation and loss of immune tolerance. Because combined-modality therapy becomes more common, clinicians should maintain a high index of suspicion for immune-mediated toxicity, particularly when findings are atypical for radiation dermatitis, to facilitate prompt diagnosis and multidisciplinary management.
引用
- Mann B, Bristol R, Beeler W, et al. Bullous Pemphigoid Induced by Whole Breast Radiation in the Setting of Concurrent Pembrolizumab: A Case Report and Review of the Literature. Pract Radiat Oncol. 2026. PMID: 42559787. doi:10.1016/j.prro.2026.06.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。